Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapeutic Agent-Induced Vulvodynia, an Experimental Model

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Vulvodynia is a chronic clinical condition associated with vulvar pain that can impair the sexual, social, and psychological life of women. There is a need for more research to develop novel strategies and therapies for the treatment of vulvodynia. Vulvodynia in experimental animal models induced via infections, allergens, and diabetes are tedious and with lessor induction rate. The objective of the study was to explore the possibility of inducing vulvodynia using a chemotherapeutic agent in a rodent model. Paclitaxel is commonly used in treating breast and ovarian cancer, whose dose-limiting side effect is peripheral neuropathy. Studies have shown that peripheral neuropathy is one of the etiologies for vulvodynia. Following paclitaxel administration (2 mg/kg i.p.), the intensity of vulvar hypersensitivity was assessed using a series of von Frey filaments (0.008 to 1 g) to ensure the induction of vulvodynia. Vulvodynia was induced from day 2 and was well sustained for 11 days. Furthermore, the induced vulvodynia was validated by investigating the potentiation of a flinch response threshold, upon topical application and systemic administration of gabapentin, a commonly used medication for treating neuropathic pain. The results demonstrate that vulvodynia was induced due to administration of paclitaxel. The fact that chemotherapeutic agent-induced vulvodynia was responsive to topical and parenterally administered gabapentin provides validity to the model. The study establishes a new, relatively simple and reliable animal model for screening drug molecules for vulvar hypersensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Harlow BL, Kunitz CG, Nguyen RH, Rydell SA, Turner RM, MacLehose RF. Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions. Am J Obstet Gynecol. 2014;210(1):40–e1-8.

    Article  Google Scholar 

  2. Reed BD, Harlow SD, Sen A, Legocki LJ, Edwards RM, Arato N, et al. x Prevalence and demographic characteristics of vulvodynia in a population-based sample. Am J Obstet Gynecol. 2012;206(2):170–e1.

    Article  Google Scholar 

  3. Ponte M, Klemperer E, Sahay A, Chren M. M. Effects of vulvodynia on quality of life. J. Am. Acad. Dermatol. 2009;60(1):70–6.

    Google Scholar 

  4. Sadownik LA. Etiology, diagnosis, and clinical management of vulvodynia. Int J Women's Health. 2014;6:437.

    Article  Google Scholar 

  5. Lynch PJ. Vulvodynia as a somatoform disorder. The J Reprod Med. 2008;53(6):390–6.

    PubMed  Google Scholar 

  6. Damsted-Petersen C, Boyer SC, Pukall CF. Current perspectives in vulvodynia. Women Health. 2009;5(4):423–36.

    Article  Google Scholar 

  7. Zolnoun DA, Rohl J, Moore CG, Perinetti-Liebert C, Lamvu GM, Maixner W. Overlap between orofacial pain and vulvar vestibulitis syndrome. The Clin J of Pain. 2008;24(3):187–91.

    Article  Google Scholar 

  8. Babula O, Danielsson I, Sjoberg I, Ledger WJ, Witkin SS. Altered distribution of mannose-binding lecithin alleles at exon I-codon 54 in women with vulvar vestibulitis syndrome. Am J Obstet Gynecol. 2004;191:762–6.

    Article  CAS  Google Scholar 

  9. Foster DC, Sazenski TM, Stodgell C. Impact of genetic variants of the interleukin receptor antagonist and melanocortin receptor genes on vulvar vestibulitis syndrome. J Reprod Med. 2004;49:503–9.

    CAS  PubMed  Google Scholar 

  10. Omoigui S. The biochemical origin of pain: the origin of all pain is inflammation and the inflammatory response, Part 2 of 3 inflammatory profile of pain syndromes. Med Hypotheses. 2007;69:1169–78.

    Article  CAS  Google Scholar 

  11. Bornstein J, Goldschmid N, Sabo E. Hyperinnervation and mast cell activation may be used as histopathology diagnostic criteria for vulvar vestibulitis. Gynecol Obstet Investig. 2004;58:171–8.

    Article  Google Scholar 

  12. Foster DC, Hasday JD. Elevated tissue levels of interleukin-1 beta and tumor necrosis factor-alpha in vulvar vestibulitis. Obstet Gynecol. 1997;89:291–6.

    Article  CAS  Google Scholar 

  13. Wesselmann U, Lai J. Mechanisms of referred visceral pain: uterine inflammation in the adult virgin rat results in neurogenic plasma extravasation in the skin. Pain. 1997;73:309–17.

    Article  Google Scholar 

  14. Bohm-Starke N, Hilliges M, Falconer C, Rylander E. Increased intraepithelial innervation in women with vulvar vestibulitis syndrome. Gynecol Obstet Investig. 1998;46:256–60.

    Article  CAS  Google Scholar 

  15. Bohm-Starke N, Hilliges M, Brodda-Jansen G, Rylander E, Torebjork E. Psychophysical evidence of nociceptor sensitization in vulvar vestibulitis syndrome. Pain. 2001;94:177–83.

    Article  Google Scholar 

  16. Pukall CF, Binik YM, Khalife S, Amsel R, Abbott FV. Vestibular tactile and pain thresholds in women with vulvar vestibulitis syndrome. Pain. 2002;96:163–75.

    Article  Google Scholar 

  17. Sutton KS, Pukall CF, Chamberlain S. Pain ratings, sensory thresholds, and psychosocial functioning in women with provoked vestibulodynia. J Sex Marital Ther. 2009;35:262–81.

    Article  Google Scholar 

  18. Giamberardino M.A, Wesselmann U, Costantini R, Czakanski P. Animal models of urogenital pain. In: Handwerker H.O, Arendt-Nielsen. L, editors. Pain models: translational relevance and applications. Washington, DC: IASP Press; 2013;183–200.

  19. Farmer MA, Taylor AM, Baily A. Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Trasnl Med. 2011;3:101ra91–1-9.

    Google Scholar 

  20. Berkley KJ, Wood E, Scofield SL, Little M. Pain. Behavioral responses to uterine or vaginal distension in the rat. Pain. 1995;61(1):121–3.

    Article  Google Scholar 

  21. Wesselmann U, Sanders C, Czakanski PP. Seattle: IASP Press. Altered CNS processing of nociceptive messages from the vagina in rats, that have recovered from uterine inflammation. Prog Pain Res Manag. 2000;16:581–8.

    Google Scholar 

  22. Danby, C. S, Margesson, L. J. Approach to the diagnosis and treatment of vulvar pain. Dermatol Ther 2010); 23(5): 485-504.

  23. Baron R. Mechanisms of disease: neuropathic pain – a clinical perspective. Nat Clin Pract Neurol. 2006;2:95–106.

    Article  Google Scholar 

  24. Kalra B, Kalra S, Bajaj S. Vulvodynia: an unrecognized neuropathic syndrome. Indian J Endocrinol Metab. 2013;17:787–9.

    Article  Google Scholar 

  25. Ali G, Fazal S, Muzaffar A, Jehan Z, Muhammad S, Robert D, et al. A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. Naunyn Schmiedeberg's Arch Pharmacol. 2015;388:1129–40.

    Article  CAS  Google Scholar 

  26. Sharma H, Esther, Yap P, Pat V, Melinda K, Spencer NJ, et al. Innervation changes induced by inflammation in the murine vagina. Neuroscience. 2018;(21):16–26.

  27. Vanegas H, Schaible HG. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain. 2000;85:9–18.

    Article  CAS  Google Scholar 

  28. TU FF, Kevin H, Miroslav. Gynecological management of neuropathic pain. Am J Obstet Gynecol. 2011;205(5):435–43.

    Article  Google Scholar 

  29. Duggett NA, Griffiths LA, Flatters SJL. Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons. Pain. 2017;158:8.

    Article  Google Scholar 

  30. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996;12:56–8.

    Article  CAS  Google Scholar 

  31. Stacey BR, Tipton KD, Owen GT, Sinclair JD, Glick RM. Gabapentin and neuropathic pain states: a case series report. Reg Anaesth. 1996;2(Suppl):65.

    Google Scholar 

  32. Bates CM, Timmins DJ. Vulvodynia - new and more effective approaches to therapy. Int J STD AIDS. 2002;13:210–2.

    Article  CAS  Google Scholar 

  33. Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol. 2008;112:579–85.

    Article  Google Scholar 

  34. Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med. 2009;10:918–29.

    Article  Google Scholar 

  35. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–73.

    Article  CAS  Google Scholar 

  36. Wall PD, Waxman S, Basbaum AI. Ongoing activity in peripheral nerve: injury discharge. Exp Neurol. 1974;45:576–89.

    Article  CAS  Google Scholar 

  37. Govrin-L R, Devor M. Ongoing activity in severed nerves: source and variation with time. Brain Res. 1978;159:406–10.

    Article  Google Scholar 

  38. Devor M. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp Brain Res. 2009;196:115–28.

    Article  CAS  Google Scholar 

  39. Schlaeger, J M, Patil, C L, Steffen, AD, Pauls, HA, Roach, KL, Thornton, P D, Hartmann, D K,Yao, Y, Suarez, M L, Hughes, T L, Wilkie, D J, Sensory pain characteristics of vulvodynia and their association with nociceptive and neuropathic pain: an online survey pilot study. 2019 ;4:2-713.

  40. De Pas TM, Mandala M, Curigliano G, Peccatori F. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue ly355703. Obstet Gynecol. 2000:1030.

  41. Chen L, Goldman-Knaub J, Pullman-Mooar S. Local therapy for fibromyalgia and nonneuropathic pain. 1st ed. In: Wallace, DJ, Crauw DJ, editors. Fibromyalgia & other central pain syndromes. Philadelphia (PA): Lippincott Williams & Wilkins. 2005:353–68.

  42. Wilton LV, Shakir S. A post marketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia. 2002;43:983–92.

    Article  Google Scholar 

  43. Carlton SM, Zhou S. Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin. Pain. 1998;76:201–7.

    Article  CAS  Google Scholar 

  44. Field JM, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain. 1999;80:391–8.

    Article  CAS  Google Scholar 

  45. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66:251–2.

    Article  CAS  Google Scholar 

  46. Updike GM, Wiesenfeld HC. Insight into the treatment of vulvar pain: a survey of clinicians. Am J Obstet Gynecol. 2005;193:1404–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA

    Srinath Rangappa, Vijay Kumar Shankar, Seongbong Jo, Michael A. Repka & S. Narasimha Murthy

  2. Institute for Drug Delivery and Biomedical Research, Bangalore, Karnataka, India

    S. Narasimha Murthy

Authors
  1. Srinath Rangappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vijay Kumar Shankar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seongbong Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael A. Repka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Narasimha Murthy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Narasimha Murthy.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rangappa, S., Shankar, V.K., Jo, S. et al. Chemotherapeutic Agent-Induced Vulvodynia, an Experimental Model. AAPS PharmSciTech 22, 95 (2021). https://doi.org/10.1208/s12249-021-01969-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-021-01969-0

KEY WORDS

Search

Navigation